SBP GROUP logs HK$10.03 million buyback; 32.70 million shares awaiting cancellation

Bulletin Express05-15 16:44

SBP GROUP (formerly Sino Biopharmaceutical Limited) disclosed that it repurchased 1.87 million ordinary shares on 15 May 2026 via the Hong Kong Stock Exchange.

• Repurchase specifics – Volume: 1.87 million shares (0.01 % of issued share capital) – Price range: HK$5.35–HK$5.37; volume-weighted average about HK$5.36 – Total consideration: HK$10.03 million

• Cumulative outstanding cancellations From 21 April to 15 May 2026 the company bought back 32.70 million shares, all designated for cancellation and not yet removed from the register.

• Share capital position – Issued shares unchanged at 18.75 billion as of 15 May 2026 – Treasury shares: none held

• Repurchase mandate utilisation – Shares authorised under mandate (granted 10 June 2025): 1.88 billion – Shares repurchased to date under the mandate: 48.05 million, equal to 0.26 % of the issued share count on the mandate date

A moratorium on new share issues or treasury-share sales is in force until 14 June 2026, in line with Hong Kong listing rules. All repurchases were executed in accordance with the Main Board Listing Rules, as confirmed by the company secretary.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103791679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103791679","market":"us","top_or_hot":-1,"title":"SBP GROUP logs HK$10.03 million buyback; 32.70 million shares awaiting cancellation","media":"Bulletin Express","content":"<p>SBP GROUP (formerly Sino Biopharmaceutical Limited) disclosed that it repurchased 1.87 million ordinary shares on 15 May 2026 via the Hong Kong Stock Exchange.</p>\n<p>• Repurchase specifics  \n – Volume: 1.87 million shares (0.01 % of issued share capital)  \n – Price range: HK$5.35–HK$5.37; volume-weighted average about HK$5.36  \n – Total consideration: HK$10.03 million</p>\n<p>• Cumulative outstanding cancellations  \nFrom 21 April to 15 May 2026 the company bought back 32.70 million shares, all designated for cancellation and not yet removed from the register.</p>\n<p>• Share capital position  \n – Issued shares unchanged at 18.75 billion as of 15 May 2026  \n – Treasury shares: none held</p>\n<p>• Repurchase mandate utilisation  \n – Shares authorised under mandate (granted 10 June 2025): 1.88 billion  \n – Shares repurchased to date under the mandate: 48.05 million, equal to 0.26 % of the issued share count on the mandate date</p>\n<p>A moratorium on new share issues or treasury-share sales is in force until 14 June 2026, in line with Hong Kong listing rules. All repurchases were executed in accordance with the Main Board Listing Rules, as confirmed by the company secretary.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SBP GROUP logs HK$10.03 million buyback; 32.70 million shares awaiting cancellation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSBP GROUP logs HK$10.03 million buyback; 32.70 million shares awaiting cancellation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-15 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP (formerly Sino Biopharmaceutical Limited) disclosed that it repurchased 1.87 million ordinary shares on 15 May 2026 via the Hong Kong Stock Exchange.</p>\n<p>• Repurchase specifics  \n – Volume: 1.87 million shares (0.01 % of issued share capital)  \n – Price range: HK$5.35–HK$5.37; volume-weighted average about HK$5.36  \n – Total consideration: HK$10.03 million</p>\n<p>• Cumulative outstanding cancellations  \nFrom 21 April to 15 May 2026 the company bought back 32.70 million shares, all designated for cancellation and not yet removed from the register.</p>\n<p>• Share capital position  \n – Issued shares unchanged at 18.75 billion as of 15 May 2026  \n – Treasury shares: none held</p>\n<p>• Repurchase mandate utilisation  \n – Shares authorised under mandate (granted 10 June 2025): 1.88 billion  \n – Shares repurchased to date under the mandate: 48.05 million, equal to 0.26 % of the issued share count on the mandate date</p>\n<p>A moratorium on new share issues or treasury-share sales is in force until 14 June 2026, in line with Hong Kong listing rules. All repurchases were executed in accordance with the Main Board Listing Rules, as confirmed by the company secretary.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1103791679","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103791679","pubTimestamp":1778834646,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SBP GROUP (formerly Sino Biopharmaceutical Limited) disclosed that it repurchased 1.87 million ordinary shares on 15 May 2026 via the Hong Kong Stock Exchange. • Repurchase specifics    – Volume:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"SBP集团回购1003万港元；3270万股等待注销","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP (formerly Sino Biopharmaceutical Limited) disclosed that it repurchased 1.87 million ordinary shares on 15 May 2026 via the Hong Kong Stock Exchange.\n• Repurchase specifics  \n – Volume: 1.87 million shares (0.01 % of issued share capital)  \n – Price range: HK$5.35–HK$5.37; volume-weighted average about HK$5.36  \n – Total consideration: HK$10.03 million\n• Cumulative outstanding cancellations  \nFrom 21 April to 15 May 2026 the company bought back 32.70 million shares, all designated for cancellation and not yet removed from the register.\n• Share capital position  \n – Issued shares unchanged at 18.75 billion as of 15 May 2026  \n – Treasury shares: none held\n• Repurchase mandate utilisation  \n – Shares authorised under mandate (granted 10 June 2025): 1.88 billion  \n – Shares repurchased to date under the mandate: 48.05 million, equal to 0.26 % of the issued share count on the mandate date\nA moratorium on new share issues or treasury-share sales is in force until 14 June 2026, in line with Hong Kong listing rules. All repurchases were executed in accordance with the Main Board Listing Rules, as confirmed by the company secretary.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103791679","isCrawlerRequest":true}